The Anthem Biosciences IPO has opened for subscription from July 14 to July 16, 2025. It is a Mainboard Book Build IPO, and the company aims to raise approximately ₹3,395 crores, including a fresh issue and an offer for sale of up to 5.96 crore equity shares. The price band for the IPO is set between ₹540 to ₹570 per share.
Anthem Biosciences is a Bengaluru-based CRDMO (Contract Research, Development and Manufacturing Organization) catering to both biotech startups and global pharmaceutical giants.
📌 Anthem Biosciences IPO Details
| IPO Details | Information |
|---|---|
| IPO Open Date | July 14, 2025 |
| IPO Close Date | July 16, 2025 |
| Listing Date | July 21, 2025 |
| Face Value | ₹2 per equity share |
| IPO Price Band | ₹540 to ₹570 |
| Issue Size | Approx ₹3,395 crores |
| Offer for Sale | 5,95,61,404 equity shares |
| Listing Exchanges | BSE & NSE |
| Retail Quota | 35% |
| QIB Quota | 50% |
| NII (HNI) Quota | 15% |
🔗 DRHP Prospectus PDF
🔗 RHP Prospectus PDF
🔗 Anchor Investors List
🔗 Anthem Biosciences Official Website
💹 IPO Market Lot & Investment Size
| Application Type | Lot Size | Shares | Amount |
|---|---|---|---|
| Retail Min | 1 | 26 | ₹14,820 |
| Retail Max | 13 | 338 | ₹1,92,660 |
| S-HNI Min | 14 | 364 | ₹2,07,480 |
| B-HNI Min | 68 | 1,768 | ₹10,07,760 |
🗓️ Important IPO Dates
| Event | Date |
|---|---|
| IPO Open | July 14, 2025 |
| IPO Close | July 16, 2025 |
| Allotment Date | July 17, 2025 |
| Refunds Initiated | July 18, 2025 |
| Shares in Demat | July 18, 2025 |
| Listing Date | July 21, 2025 |
📈 Anthem Biosciences Financial Performance
| Year | Revenue (₹ Cr) | PAT (₹ Cr) | Assets (₹ Cr) |
|---|---|---|---|
| 2022 | 1,280.24 | 405.54 | 1,618.87 |
| 2023 | 1,133.99 | 385.19 | 2,014.46 |
| 2024 | 1,483.07 | 367.31 | 2,398.11 |
| 2025 | 1,930.29 | 451.26 | 2,807.58 |
Anthem Biosciences has shown consistent revenue and profit growth, making it an attractive IPO for long-term investors.
📊 Valuation & Key Financial Ratios
| KPI | Value |
|---|---|
| Return on Equity (RoE) | 20.82% |
| Return on Capital Employed | 27.64% |
| EBITDA Margin | 36.81% |
| PAT Margin | 23.38% |
| Debt to Equity Ratio | 0.05 |
| EPS (FY25) | ₹8.07 |
| NAV | ₹43.10 |
🧪 About Anthem Biosciences Ltd
Founded in 2006, Anthem Biosciences is a full-service CRDMO that offers solutions from drug discovery to commercial manufacturing. It specializes in fermentation-based APIs, including probiotics, enzymes, peptides, and biosimilars.
- Over 150 global customers
- More than 600 employees including chemists, biologists, and engineers
- Strong capabilities in NCEs and NBEs
🧾 Objects of the Issue
Note: The company will not receive any proceeds from this offer. All funds will go to selling shareholders post expenses and taxes.
📚 Peer Comparison
| Company | EPS | RoNW (%) | PE Ratio | Revenue (₹ Cr) |
|---|---|---|---|---|
| Syngene International | 12.35 | 11.05% | 51.54 | 3,642.40 |
| Sai Life Sciences | 8.83 | 10.96% | 92.18 | 1,694.57 |
| Suven Life Sciences | 10.52 | 13.61% | 97.29 | 1,197.58 |
| Divi’s Laboratories | 82.53 | 15.35% | 83.22 | 9,360.00 |
Compared to peers, Anthem Biosciences shows strong margins and growth potential, although P/E is not available pre-IPO.
📌 How to Apply for Anthem Biosciences IPO?
You can apply using:
- ASBA via your bank’s net banking portal
- UPI-based applications through brokers like Zerodha, Groww, Upstox
- Offline forms via traditional brokerage firms
🔍 IPO Reviews & Analyst Recommendations
Several market analysts and brokerage houses have rated this IPO positively:
- ICICIdirect – Subscribe
- Hem Securities – May Apply
- Sharekhan – Neutral
- Swastika Investmart – Subscribe for Long-Term
Keep checking the Anthem Biosciences IPO GMP page for daily updates on grey market premium.
📬 IPO Registrar Contact
KFin Technologies Limited
Website: https://kosmic.kfintech.com/ipostatus/
Phone: 040-67162222
Email: anthem.ipo@kfintech.com
📌 FAQs on Anthem Biosciences IPO
Q1. What is the Anthem Biosciences IPO GMP today?
Check live updates on IPO GMP here.
Q2. What is the Anthem Biosciences IPO listing date?
July 21, 2025 on BSE and NSE.
Q3. What is the lot size and minimum investment?
One lot is 26 shares; minimum investment is ₹14,820.
Q4. Is Anthem Biosciences IPO good for long-term?
Given its strong fundamentals, revenue growth, and margins, it could be a long-term wealth creator.
🔚 Conclusion: Should You Invest in Anthem Biosciences IPO?
With robust financials, strong promoter backing, and niche CRDMO positioning, Anthem Biosciences IPO presents an attractive opportunity. Investors looking for long-term value creation in the pharma and biotech space may consider applying.